The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

Corvus Pharmaceuticals' Soquelitinib shows promise for PTCL & more, but financial risks and competition raise concerns. Learn more about CRVS stock here.

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

(RTTNews) - Pfizer Inc. (PFE) Wednesday announced the FDA approval of its supplemental Biologics License Application or sBLA for ADCETRIS otherwise known as brentuximab vedotin combined with ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for large B-cell lymphoma ...

The Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with Revlimid (lenalidomide) and Rituxan (rituximab) for the treatment of adults with relapsed or ...

In her budget speech, Finance Minister Nirmala Sitharaman announced the exemption of 36 drugs used to treat cancer, rare diseases, and other severe chronic diseases from the basic customs duty ...

The FDA has approved Pfizer’s supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adults ...

Notably, 23% of patients had to discontinue brentuximab vedotin owing to neuropathy, a rate higher than that observed in clinical trials such as ECHELON-1. It’s not that I’m against BV+AVD ...